Vaxcyte, Inc.
NASDAQ:PCVXBiotechnology
+$1.94 today
- Market cap
- $9.26B
- Beta
- 1.24
- P/E (TTM)
- -7.8
- EPS (TTM)
- -$6.78
Volume 1.13M
Average 1.44M
PCVX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Vaxcyte, Inc.NASDAQ: PCVX
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development grows, but more slowly than its trailing trend
Q2 FY2026 research & development of $267.85M rose 37.9% year over year, behind the +74.2% change in trailing-twelve-month research & development. Sequentially, it fell 14.4% from the prior quarter. Over 3 fiscal years it compounded at +67.4% a year.
Context
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +37.9% toward the trailing-twelve-month pace of +74.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 794.31M USD
- Year-over-year change
- +66.6%
- 4-year CAGR
- +78.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 794.31M | +66.6% |
| FY2024 | 2024-12-31 | 476.64M | +43.4% |
| FY2023 | 2023-12-31 | 332.34M | +96.1% |
| FY2022 | 2022-12-31 | 169.45M | +116.1% |
| FY2021 | 2021-12-31 | 78.41M | — |
Research & Development vs competitors
How PCVX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +74.2% is the highest of 9, against a peer median of -1.9%.
- Over three fiscal years its annual growth of +67.4% compares with a peer median of -4.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $11.05B USD | +7.0% | -3.0% | 17.3% | |
| LTM Jun 2026 | £9.2B GBP | +31.8% | +11.1% | 27.7% | |
| LTM Sep 2026 | $2.66B USD | -23.6% | -1.7% | 105.3% | |
| LTM Jun 2026 | $1.03B USD | +74.2% | +67.4% | — | |
| LTM Mar 2026 | $446.24M USD | -15.0% | -3.0% | 681.3% | |
| LTM Mar 2026 | $345.36M USD | -10.9% | -35.2% | 57.9% | |
| LTM Sep 2026 | $252.23M USD | +33.2% | -5.7% | 138.2% | |
| LTM Mar 2026 | $98.25M USD | -44.3% | -8.8% | 216.6% | |
| LTM Mar 2026 | €85.57M EUR | +12.6% | -6.7% | 54.7% | |
| Peer median (excluding PCVX) | — | -1.9% | -4.4% | 81.6% | |
Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 78.41M | 169.45M | 332.34M | 476.64M | 794.31M |
| Selling, General & Admin | 25.26M | 39.81M | 60.7M | 92.9M | 129.37M |
| Operating Expenses | 103.67M | 232.26M | 468.04M | 569.55M | 923.68M |
| Depreciation & Amortization | 3.46M | 9.45M | 10.17M | 15.85M | 24.86M |
| EBITDA | (96.61M) | (214.03M) | (392.1M) | (448.08M) | (741.77M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (103.67M) | (232.26M) | (468.04M) | (569.55M) | (923.68M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 344K | 8.36M | 62.91M | 109.99M | 119.72M |
| Interest Expense | 7K | 2K | 0 | 0 | 0 |
| Other Income / Expenses | 3.59M | 8.77M | 65.78M | 105.62M | 157.05M |
| Income Before Tax | (100.08M) | (223.49M) | (402.27M) | (463.93M) | (766.63M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (100.08M) | (223.49M) | (402.27M) | (463.93M) | (766.63M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.93) | (3.44) | (4.14) | (3.80) | (5.63) |
| EPS (Diluted) | (1.93) | (3.44) | (4.14) | (3.80) | (5.63) |
| Weighted Avg Shares | 51.92M | 64.88M | 97.16M | 122M | 136.09M |
| Weighted Avg Shares (Diluted) | 51.92M | 64.88M | 97.16M | 122M | 136.09M |
Vaxcyte, Inc.
NASDAQ:PCVX
Intrinsic Alpha fair value
Locked
Current Price
$58.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.